Bill 32 inserts a new paragraph into section 16 of the Mental Health Act that expressly lists “providing to a patient a professional service, or care or treatment, authorized by the director under this Act,” and it expressly includes treatments described in a consent-to-treatment form signed under section 8(a). Separately, the bill repeals subsection (1) of section 31 and rewrites the opening of subsection (2) to make that provision explicitly apply to patients detained in designated facilities under sections 22, 28, 29, 30 or 42 and to patients released on leave or transferred to approved homes under sections 37 or 38.
Those are compact textual changes with practical consequences: the amendment to section 16 codifies that director-authorized services include treatments set out in particular consent forms, which affects how clinicians and administrators treat consent documentation and director approvals. The section 31 edits refocus the statute’s coverage on a clearly defined group of patients, creating operational implications for facilities, clinicians, and legal advisers about which patients trigger the rights, duties or procedures tied to section 31.
At a Glance
What It Does
The bill adds a new clause to section 16 recognizing director-authorized professional services and explicitly including treatments described in a consent-to-treatment form signed under section 8(a). It also removes subsection (1) of section 31 and replaces the opening phrase of subsection (2) so the provision applies to patients detained under specified hospitalization sections and to those released on leave or transferred to approved homes.
Who It Affects
Primary actors affected are patients detained under sections 22, 28, 29, 30 or 42, patients on authorized leave or transferred to approved homes under sections 37 or 38, the director (and deputy directors) under the Act, clinicians who rely on consent forms, facility administrators and legal teams advising on admission, treatment and transfers.
Why It Matters
By declaring certain consent forms and director authorizations as an explicit basis for providing care, the bill reduces ambiguity about lawful treatment authority and shifts operational responsibility to implement that clarity. Narrowing and clarifying section 31’s application will require policy and practice changes in designated facilities and may affect procedural safeguards tied to that section.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill makes two concise but consequential edits to the Mental Health Act. The first is an addition to the list of things the director can authorize under section 16: the director may authorize providing a professional service, or care or treatment to a patient, and that list now expressly includes treatments described in a consent-to-treatment form signed under section 8(a).
In practical terms, the legislature is tying two things together: the director’s statutory authorization power and the express contents of a particular consent form used under the Act.
That linkage changes how clinicians and administrators should read consent documentation. Where a patient has a consent-to-treatment form signed as described in section 8(a), the bill makes clear that the treatment described on that form falls within the director’s authority to authorize care under the Act.
That should reduce uncertainty about whether a director’s authorization is required for treatments covered by such a form and may streamline decisions about providing care that is already documented by consent forms.The second amendment alters section 31 by removing subsection (1) outright and by replacing the lead-in to subsection (2) with a targeted list of patient statuses: detained in a designated facility under sections 22, 28, 29, 30 or 42, released on leave, or transferred to an approved home under sections 37 or 38. The result is a tighter statutory trigger: section 31 will apply only to patients who meet those specific conditions.
Operationally, that forces hospitals, health authorities and lawyers to re-check which discharge, review or procedural rules in section 31 continue to apply to which patients and to update intake, transfer and leave protocols.Both edits come into force immediately on Royal Assent. Because the bill changes the statutory scaffolding that clinicians and administrators use to justify treatment and to determine who is covered by section 31, health authorities should treat this as an instruction to revise internal policies, training, and documentation practices so they align with the clarified statutory language.
The Five Things You Need to Know
The bill adds paragraph (b.4) to section 16 of the Mental Health Act to cover “providing to a patient a professional service, or care or treatment, authorized by the director under this Act,” and explicitly includes treatment described in a consent-to-treatment form signed under section 8(a).
The bill repeals subsection (1) of section 31 and changes subsection (2)’s opening words so section 31 applies to patients detained under sections 22, 28, 29, 30 or 42, and to patients released on leave or transferred to an approved home under sections 37 or 38.
By cross-referencing section 8(a) in section 16, the Act treats certain signed consent-to-treatment forms as falling within the director’s authorization power for providing care.
The amendments take effect immediately: the Act comes into force on the date of Royal Assent.
Practically, the changes place the onus on directors, facility administrators and clinicians to ensure policies and documentation reflect that specific consent forms and the listed detention/transfer statuses determine when director authorization and section 31’s rules apply.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Director-authorized services now explicitly include certain consented treatments
This provision adds paragraph (b.4) to section 16 so that the director’s authorization power is expressly described to include providing professional services or care and treatment that the director authorizes. The paragraph goes on to say these authorized treatments include treatments described in a consent-to-treatment form signed under section 8(a). The practical implication is legal recognition that a specific kind of signed consent form sits within the director’s authorization framework, which reduces doubt for clinicians whether a treatment documented on that form has statutory backing.
Removes an existing subsection that currently forms part of section 31
The bill deletes subsection (1) of section 31. Removing a standalone subsection can have structural and procedural consequences because later references, transitional language or administrative practices that relied on that paragraph will need review. Health authorities and counsel must identify what operational rules or safeguards were tied to the deleted text and determine whether policy or regulatory updates are necessary to preserve intended protections or procedures.
Targets section 31 to detained, on-leave or transferred patients under specific sections
The amendment replaces the opening phrase of subsection (2) so that section 31’s application is expressly limited to a patient who is detained in a designated facility under sections 22, 28, 29, 30 or 42, or who is released on leave or transferred to an approved home under sections 37 or 38. That wording narrows the statutory trigger language and requires administrators to map which patients—by legal status under those listed sections—must be handled under the rules attached to section 31, while others fall outside its scope.
Immediate effect on Royal Assent
The Act states it comes into force on the date of Royal Assent. There is no delayed implementation window or regulation-making proviso in the bill text itself, so affected bodies should treat the changes as operative immediately and plan updates to operational guidance, forms and training without delay.
This bill is one of many.
Codify tracks hundreds of bills on this topic across all five countries.
Explore this topic in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Clinicians and treating teams — they gain clearer statutory footing when providing treatments described on consent-to-treatment forms, reducing ambiguity about whether director authorization supports clinically indicated care.
- The director’s office — the explicit text strengthens the director’s statutory toolkit by tying consent documentation into the director’s authorization powers, simplifying decision-making about what the director can authorize.
- Health authority administrators — clearer statutory triggers for section 31 make it easier to design policies that apply to detained, on-leave or transferred patients and to align operational procedures with the Act.
- Patients whose treatment is documented on section 8(a) consent forms — those patients (and their care teams) will benefit from reduced administrative friction when the documented treatment aligns with director authorization, which can speed delivery of planned care.
Who Bears the Cost
- Facility administrators and health authorities — they must review and revise intake, consent, transfer and leave procedures, update forms and retrain staff to reflect the narrowed scope of section 31 and the new linkage between consent forms and director authorization.
- Legal and compliance teams — they will need to reassess previously relied-on protections or procedures linked to the repealed subsection (1), and to update advice on when section 31 applies to particular patient statuses.
- Patient advocates and oversight bodies — monitoring and enforcement responsibilities may increase as they interpret whether the new wording preserves safeguards previously attached to section 31 or inadvertently limits them.
Key Issues
The Core Tension
The central dilemma is between enabling timely, director-authorized treatment (including care documented by certain signed consent forms) and preserving procedural safeguards around consent, capacity and the application of section 31; the bill clarifies authority in one respect while leaving unanswered how that authority should be exercised without eroding patient-protection mechanisms.
Two implementation tensions stand out. First, the bill ties certain consent forms into the director’s authorization power without spelling out how consent validity, timing, or capacity assessments interact with that authority.
The text does not clarify whether a consent form under section 8(a) must be contemporaneous, witnessed in a particular way, or re-confirmed when a patient’s status changes (for example, from voluntary to detained), leaving operational gaps for clinicians and administrators to fill. Second, deleting subsection (1) of section 31 while tightening subsection (2) changes the statute’s structure but not its ancillary regulations or policies; if previous procedural safeguards or reporting duties were anchored in the removed paragraph, they may lapse unless the ministry, health authorities or regulations re-establish them.
Practically, health systems must decide whether the bill’s clarity reduces litigation risk (by removing ambiguity) or increases it (by creating new uncertainty around consent-form validity and the consequences of subsection removal). The absence of transitional language or explicit guidance in the bill means much will turn on internal policy, clinical standards and possibly how regulators or courts interpret the new wording in contested cases.
There's more to this law than the bill.
Codify Laws traces every connection across the legislative lifecycle.